IPSE'S AUTHORS LAST 24h
Check all the Authors in the last 24h
IPSEs IN THE LAST 24H
  • Sue Mi Terry
    Sue Mi Terry “Now is not the time to lift sanctions, either. Now, in fact, is the time to double down. If Biden wants to prevent North Korea from acting out, he needs to first provide the government with new incentives to talk-and that means new restrictions Washington can use as carrots. Biden, in other words, needs to take North Korean policy off autopilot and launch a proactive effort to deter Pyongyang. Otherwise, he risks encouraging an already emboldened Kim to stage a major provocation.” 12 hours ago
  • Christopher Cavoli
    Christopher Cavoli “Russians don't have the numbers necessary to do a strategic breakthrough. More to the point, they don't have the skill and capability to do it, to operate at the scale necessary to exploit any breakthrough to strategic advantage. They do have the ability to make local advances and they have done some of that.” 13 hours ago
  • Nazar Voloshin
    Nazar Voloshin “The situation in the Kharkiv sector remains complicated but is evolving in a dynamic manner. Our defence forces have partially stabilised the situation. The advance of the enemy in certain zones and localities has been halted.” 18 hours ago
  • Volodymyr Zelenskiy
    Volodymyr Zelenskiy “The situation in the Kharkiv region is generally under control, and our soldiers are inflicting significant losses on the occupier. However, the area remains extremely difficult.” 18 hours ago
  • Bezalel Smotrich
    Bezalel Smotrich “Defense Minister Gallant announced today his support for the establishment of a Palestinian terrorist state as a reward for terrorism and Hamas for the most terrible massacre of the Jewish people since the Holocaust.” 18 hours ago
  • Yoav Gallant
    Yoav Gallant “I must reiterate … I will not agree to the establishment of Israeli military rule in Gaza. Israel must not establish civilian rule in Gaza.” 19 hours ago
View All IPSEs inserted in the Last 24h

Covid-19 vaccine - UK

Page with all the IPSEs stored in the archive related to the Context Covid-19 vaccine - UK.
The IPSEs are presented in chronological order based on when the IPSEs have been pronounced.

“here is some research that has taken place already suggesting that only one in four people in the UK are now in a position whereby they can get to vaccination centres. [But] there are plans to roll out more vaccination centres. UK has done quite well with administering vaccines so far, in that it has a supply line that is better than Europe it would seem because of the quicker approvals. But it can’t afford to be complacent because of the figures – now five days in a row we’ve had record numbers of infection rate rises, and we have a situation now whereby the UK is likely to overtake Italy as the worst hit [European] country.”

author
Al Jazeera’s journalist reporting from London
Read More

“We’re working very closely with our UK partners to understand what went on with respect to those allergic reactions. FDA is the gold standard for regulatory approval or authorization of medical products. If our career scientists say that the vaccine is safe and effective, I have complete confidence in that decision, and I think the American people should as well.”

author
U.S. Food and Drug Administration Commissioner
Read More

“This really feels like the beginning of the end. It’s been a really dreadful year, 2020 - all those things that we are so used to, meeting friends and family, going to the cinema, have been disrupted. We can get those back. Not tomorrow. Not next week. Not next month. But in the months to come.”

author
Medical director for the National Health Service in England
Read More

“If I use the U.K. as an example, we got approval at 1:00 am in the morning. We approved [the] release of the vaccine and shipped it within 24 hours. Certainly from the discussions that we've had, Canada is in a good position to approve the vaccine shortly. Upon approval, we then release the vaccine and then it is shipped. We've already produced the vaccine and reserved doses for Canada.”

author
Chief business and chief commercial officer of Germany's BioNTech
Read More
IPSEs by Author
IPSEs by Country
arrow